Journal of pharmaceutical and biomedical analysis
June 9, 2008
Simona Pichini, Mitona Pujadas, Emilia Marchei et al.
59 citations
A liquid chromatography-mass spectrometry (LC-MS) method was developed to measure ten designer drugs—including MDMA, several 2C-series phenethylamines, m-CPP, and tryptamines—in urine samples from 32 consumers. Solid-phase extraction at pH 6 was applied to both non-hydrolyzed and enzymatically hydrolyzed urine, with 3,4-methylendioxypropylamphetamine (MDPA) as an internal standard. Chromatographic separation used a C18 column with a gradient of ammonium bicarbonate and acetonitrile, and detection was performed in single ion monitoring mode with electrospray ionization. Limits of quantification ranged from 20 to 60 ng/mL, calibration curves were linear to 2000 ng/mL, and mean recoveries were 55.4–95.6%. Higher analyte concentrations in hydrolyzed samples indicated the presence of conjugated compounds.
Frontiers in psychiatry
January 1, 2024
Pablo Sabucedo, Oscar Andión, Robert A Neimeyer et al.
4 citations
A protocol describes a clinical trial testing whether ayahuasca-assisted Meaning Reconstruction therapy reduces prolonged grief symptoms more than therapy alone or no treatment. At least 69 people who lost a first-degree relative within the prior year and scored 40 or higher on the Texas Revised Inventory of Grief will be assigned to one of three groups: ayahuasca-assisted therapy, therapy alone, or no treatment. The therapy involves nine online sessions; the ayahuasca group also attends two group sessions with the substance. Grief severity, quality of life, post-traumatic growth, and other measures will be assessed at baseline, after treatment, and at three months. This is the first trial to empirically examine psychedelic-assisted psychotherapy for grief.
Frontiers in psychiatry
January 1, 2025
Pablo Sabucedo, Oscar Andión, Robert A Neimeyer et al.
correction
A three-arm, non-randomized controlled trial protocol compares Ayahuasca-assisted Meaning Reconstruction therapy (A-MR) with Meaning Reconstruction therapy alone and a no-treatment control for people who lost a first-degree relative within the prior 12 months. The authors hypothesize that A-MR will produce greater reductions in normal and pathological grief symptoms, and greater improvements in quality of life and posttraumatic growth, than either control condition. The rationale draws on neurobiological evidence that ayahuasca stimulates neuroplasticity and on psychological evidence that psychedelic experiences can facilitate meaning reconstruction and cognitive reappraisal. No controlled studies have tested psychedelic-assisted therapy for prolonged grief disorder.